Search
for
Sort by
Research 30 of 1000+
- Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double‐blind, placebo‐controlled, phase 1B clinical trial
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- Efficacy of autologous dermal sheath cup cell transplantation in male and female pattern hair loss: A Single‐Arm, Multi‐Center, phase III equivalent clinical study
- A Phase III, Multicenter, Parallel-Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam Versus Vehicle in Women With Female Pattern Hair Loss.
- ESDR586 - Interest of Silybum marianum extract, Manganese PCA and Lespedeza capitata extract in a new anti-hair loss serum to stimulate hair growth and prolong anagen phase
- Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- Photobiomodulation therapy and 5% minoxidil in female pattern hair loss: a case series focusing on hair growth phases over a shorter timeframe
- 41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata
- 1077 Efficacy and safety of ENERGI-F701 solution versus 2% minoxidil solution for female pattern hair loss: a phase II, multi-center, randomized, double-blind, head-to-head, parallel trial
- 586 Interest of Silybum marianum extract, Manganese PCA and Lespedeza capitata extract in a new anti-hair loss serum to stimulate hair growth and prolong anagen phase
- Faculty Opinions recommendation of Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study.
- Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study
- The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study
- Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study.
- Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
- 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study
- ISID1077 – Efficacy and safety of ENERGI-F701 solution versus 2% minoxidil solution for female pattern hair loss: a phase II, multi-center, randomized, double-blind, head-to-head, parallel trial
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- Faculty Opinions recommendation of Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double-blind, placebo-controlled, phase 1B clinical trial.
- Correction to “Efficacy of Autologous Dermal Sheath Cup Cell Transplantation in Male and Female Pattern Hair Loss: A Single‐Arm, Multi‐Center, Phase III Equivalent Clinical Study”
- Correction to ‘Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study’
- Morus alba Root Extract Induces the Anagen Phase in the Human Hair Follicle Dermal Papilla Cells
- Hair Loss in Children
- A Practitioner's Guide to Hair Loss Part 1—History, Biology, Genetics, Prevention, Conventional Treatments, and Herbals
- Isotretinoin and Hair Loss: A Clinical Perspective and Literature Review
- A patient with diffuse hair loss
- Hair loss in women